| Name | Title | Contact Details |
|---|---|---|
Jon Miller |
Chief Technology Officer (CTO) | Profile |
Blue Matter Consulting is a management consulting firm dedicated to the life sciences industry, particularly in pharmaceuticals and biotechnology. Founded in 2012, the company has grown from a single office to a global presence with locations in the United States, Europe, and India. The leadership team, including managing partners Ashwin Dandekar, Emily Hua, and George Schmidt, guides the firms strategic growth. The firm offers a wide range of services to help life sciences companies maximize value. These services include new product planning, launch strategy and management, commercial strategy for existing products, market access strategy, corporate strategy, transaction support, and organizational design. Blue Matter also focuses on specific therapeutic areas such as oncology and rare diseases, providing tailored strategies and solutions. With a diverse client base of over 250 companies, including many top global biopharmaceutical firms, Blue Matter Consulting is recognized for its strategic expertise and personalized service in the life sciences sector.
BMW of Buena Park is one of the largest and most popular BMW dealerships in the Buena Park area. Our dealership features an extensive inventory of new and pre-owned BMW vehicles for sale, exclusive BMW lease specials and financing offers, a state-of-the-art service center, and an experienced team of BMW enthusiasts ready to assist you with any request you may have.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Reef Aquaria Design (RAD) is committed to creating custom sustainable, living aquarium ecosystems.